Similar articles

• The role of 131I-MIBG in high-risk neuroblastoma treatment.

  Lessig MK. Lessig MK. J Pediatr Oncol Nurs. 2009 Jul-Aug;26(4):208-16. doi: 10.1177/1043454209340316. J Pediatr Oncol Nurs. 2009. PMID: 19726792 Review.
• Letter to the editor.

  Kono Y, Shimizu Y, Wakatsuki Y, Yasui N, Aso T, Kawamoto H, Kurihara H. Kono Y, et al. Radiat Prot Dosimetry. 2015 Mar;163(4):533-4. doi: 10.1093/rpd/ncu278. Epub 2014 Sep 16. Radiat Prot Dosimetry. 2015. PMID: 25227441 No abstract available.
• Treatment of advanced neuroblastoma in children over 1 year of age: the critical role of ¹³¹I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen.

  Mastrangelo S, Rufini V, Ruggiero A, Di Giannatale A, Riccardi R. Mastrangelo S, et al. Pediatr Blood Cancer. 2011 Jul 1;56(7):1032-40. doi: 10.1002/pbc.22986. Epub 2011 Feb 22. Pediatr Blood Cancer. 2011. PMID: 21344615
• Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma.

  Takahashi H, Manabe A, Aoyama C, Kamiya T, Kato I, Takusagawa A, Ogawa C, Ozawa M, Hosoya R, Yokoyama K. Takahashi H, et al. Pediatr Blood Cancer. 2008 Mar;50(3):676-8. doi: 10.1002/pbc.21126. Pediatr Blood Cancer. 2008. PMID: 17243128
• Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma.

  Gaze MN, Gains JE, Walker C, Bomanji JB. Gaze MN, et al. Q J Nucl Med Mol Imaging. 2013 Mar;57(1):66-78. Q J Nucl Med Mol Imaging. 2013. PMID: 23474636 Review.